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A B S T R A C T
D-dimer is a useful diagnostic biomarker for deep vein thrombosis or pulmonary embolism, collectively referred
to as venous thromboembolism (VTE). The ability to detect in real-time the amount of D-dimer with a fast and
reliable method is a key step to anticipate the appearance of these diseases. Here, the results of a highly specific
and sensitive biosensor for the detection of D-dimer based on lossy mode resonance in fiber optics are presented.
The unique features of specialty fibers in light management integrated with microfluidics allow detecting D-
dimer in human serum with a detection limit of 100 ng/mL, a value 5-fold below the clinical cutoff value.
Comparison of the results achieved with mass-spectrometry-based proteomics, which allows for the identifica-
tion of beta- and gamma-chains of fibrinogen, demonstrates the ability of our platform to specifically (>90%)
recognize D-dimer. Therefore, this technology potentially represents a paradigm shift in the development of a
simple, high-specificity and label-free biosensing platform, which can be applied to speed up diagnostic
healthcare processes of venous thromboembolism toward an early diagnostic and personalized treatment system.
1. Introduction
D-dimer antigen, the smallest product originated from cross-linked
fibrin degradation, is used, above a cutoff value, as a biomarker for
deep vein thrombosis or pulmonary embolism, collectively referred to
as venous thromboembolism (VTE) (Adam et al., 2009; Kogan et al.,
2016). About 10 million cases of VTE occur every year, thereby re-
presenting the third leading vascular disease after acute myocardial
infarction and stroke (Raskob et al., 2014), and the diagnostic work-up
of suspected VTE includes the sequential application of a clinical de-
cision rule and D-dimer testing (Di Nisio et al., 2016). Recently, D-
dimer assays are routinely used to predict which patients are more
likely to suffer recurrent thrombosis when anticoagulant treatments are
stopped (Linkins and Takach Lapner, 2017).
Moreover, D-dimer can also be used as a predictive value for major
adverse cardiovascular events (MACE) and non-coronary artery bypass
grafting (non-CABG) major bleeding (Kikkert et al., 2014). However,
despite the importance of D-dimer monitoring by the clinicians, D-
dimer assays are highly variable, depending on the method of capture
and on the instrumentation used (Longstaff et al., 2016; Olson et al.,
2013; Spannagl et al., 2005). The clinical cutoff value of D-dimer is
0.5 μg/mL (manufacturer's recommended threshold for STA®-Liatest®
D-di; Stago, Asnières sur Seine Cedex, France) (Linkins and Takach
Lapner, 2017; Marill, 2008; Weitz et al., 2017). This value is used, once
exceeded, as a screening tool for acute aortic dissection (Shimony et al.,
2011), and the sensitivity and specificity of D-dimer above this cutoff
value for cardioembolic subtype are 78% and 79%, respectively
(Bernard et al., 2010). Therefore, it turns out obvious that measuring
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and controlling the amount of D-dimer is critical for preventing some
important diseases. As reported in (Di Nisio et al., 2007), taking into
account more than 300 D-dimer test evaluations described in 184 dif-
ferent articles, enzyme-linked immunosorbent assays (ELISA), enzyme-
linked fluorescent assays (ELFA) and quantitative latex agglutination
assays (QLAA) were more sensitive than whole-blood agglutination
assays. Therefore, the whole-blood D-dimer assay should not be used
(Weitz et al., 2017). In addition to this, despite there are few works on
sensors for D-dimer detection (Bourigua et al., 2010; Chebil et al., 2010;
Gao et al., 2015; Grant; Glass, 1999; Koukouvinos et al., 2016), none of
them makes use of a label-free detection approach where the interac-
tion of D-dimer with the sensing surface is monitored in real time.
Fiber optics, the best platform for communications and light man-
agement, is a good candidate to address the challenge and, at the same
time, features unique peculiarities such as small size, lightweight, im-
munity to electromagnetic interferences and utilization in harsh en-
vironments. However, it is sometimes discarded in biosensing because
of its low sensitivity.
During the last years, much progress has been done towards im-
proving this characteristic. Different sensing mechanisms and geome-
tries have been explored (fiber Bragg gratings, interferometers, pho-
tonic crystal fiber, or microstructured fibers) (Liu et al., 2018; Wu et al.,
2009), which allow obtaining devices with improved properties and
performances that can be considered as a lab-on-fiber (Principe et al.,
2017). The combination of the previous geometries with the nanode-
position of a thin-film has increased even more the domains of appli-
cation and the potential of optical fibers (Caucheteur et al., 2016;
Chiavaioli et al., 2017a; Stern et al., 2017). Not only the deposition of a
nanocoating sensitive to a specific parameter turns the optical fiber into
an environmental sensor, a chemical sensor or a biosensor, but also the
nanocoating can be used as an element that increases the inherent
sensitivity of the device. As an example, with the mode transition
phenomenon it is possible to enhance the sensitivity in long period
gratings (LPGs) and single-mode multimode single-mode (SMS) fiber
configuration by more than one order of magnitude (Cusano et al.,
2006; Del Villar et al., 2005). In other cases, the nanocoating is re-
sponsible for the generation of resonances related to physical phe-
nomena such as surface plasmon resonance (SPR) (Gramotnev and
Bozhevolnyi, 2010; Hoa et al., 2007; Homola, 2008) or lossy mode
resonance (LMR) (Kosiel et al., 2018; Paliwal and John, 2015; Tiwari
et al., 2017), whose the spectral shift of the resonance is used as a
parameter to detect changes in the thin-film itself or in the subsequent
deposition of additional layers.
Despite LMRs are not as well known as SPRs, they possess very in-
teresting features, such as the possibility to tune the position of the
resonance at any wavelength in the optical spectrum from the visible to
NIR, just by controlling the thickness of the nanocoating, and the op-
portunity to use alternative materials (i.e. polymers and metallic
oxides) to the metallic ones used for SPRs (Del Villar et al., 2017).
Moreover, by means of the combination of the deposition of nanometric
thin-films that generate LMRs with exotic fiber geometries, such as D-
shaped fibers, it is possible to obtain sensitivities of more than 1× 106
nm per refractive index unit (nm/RIU) in the silica region (1.45 RIU)
and of more than 1.4× 104 nm/RIU in the water region (1.33 RIU)
(Arregui et al., 2016). Since the sensitivity to refractive index (RI) is
often used as a test for the prediction of the device performance, these
values indicate the potential of this type of devices when used as a
biosensor. Based on this approach, it has been possible to detect im-
munoglobulin G at femtomolar concentration in human serum
(Chiavaioli et al., 2018).
In the present paper, we describe a simple, high-specificity and
label-free LMR-based biosensing platform consisting of a nanocoated D-
shaped fiber for the real-time monitoring of D-dimer, which is a key
advance towards theranostic treatments of VTE for personalized med-
icine. Thanks to the very sensitive approach integrated with micro-
fluidics, a detection limit of 100 ng/mL (500 pM) was achieved in
human serum, a value 5-fold below the clinical cutoff value.
Comparison of the results achieved with mass-spectrometry-based
proteomics, which was used to prove the grafting of D-dimer to the
fiber surface through peptide sequencing and bioinformatics protein
identification, also demonstrates the ability of the proposed platform to
specifically (>90%) recognize D-dimer in diluted and undiluted bio-
logical matrices and its reliability.
2. Materials and methods
2.1. Reagents
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC) and N-hydroxysuccinimide (NHS) were purchased from Thermo
Fisher Scientific. The methacrylic acid/methacrylate copolymer
(Eudragit® L100) was purchased from Evonik Health Care. Ethanol
(EtOH), phosphate-buffered saline (40mM PBS, pH 7.4), bovine serum
albumin (BSA) and the human D-dimer protein were purchased from
Sigma Aldrich Inc. The corresponding high-affinity D-dimer antibody
(Monoclonal mouse antibody, anti-D-dimer DD2), C-reactive protein
and human serum were purchased from HyTest Ltd. Electrophoresis
reagents were purchased from Bio-Rad: Urea (GE Healthcare Life
Science), thiourea (GE Healthcare Life Science), and DTT (Acròs
Organics), and trypsin from Promega.
2.2. Optical sensing and microfluidic system
The proposed optical sensing system is based on the lossy mode
resonance, a technology based on enhancement of the evanescent field
of the modes guided in the optical fiber due to the guidance of a mode
in a nanometric thin-film whose real part of the RI is higher than that of
the fiber substrate and whose imaginary part is low but not negligible
(Del Villar et al., 2017). With a side polished (D-shaped) optical fiber,
the width of the LMR resonance generated in the optical spectrum is
reduced to such a point that this allows for an accurate measurement of
the wavelength shift caused by changes in the outer medium (i.e. the
modification of the surrounding RI or the deposition of an overlay
material (Arregui et al., 2016)). In addition, the sensitivity of LMR-
based devices is improved if the RI of the material deposited on the
fiber is as high as possible (Del Villar et al., 2012). In a previous work, it
was demonstrated with a similar structure, i.e. a cladding removed
multimode fiber, that the use of SnO2-x as coating material is better than
ITO, since better performances were attained in terms of both refractive
index sensitivity (Table 1) and limit of detection (Chiavaioli et al.,
2018). The ellipsometric measurements confirmed the theory that a
higher refractive index (real part) leads to a better sensitivity: in the
used wavelength range, ranging from 1250 nm to 1750 nm, the re-
fractive index of SnO2-x is roughly 1.9, whereas it is 1.83 for ITO. In
addition, it was also shown that the optical platform is critical for the
performance of the biosensing system: if a D-shaped fiber is used in-
stead of a cladding removed multimode fiber, the LOD can be improved
by three orders of magnitude. This justifies the selection of SnO2-x as
coating material together with a D-shaped fiber. Amorphous silicon,
IGZO and ZnO have also been explored with D-shaped fibers (Andreev
et al., 2005, 2008; Ozcariz et al., 2019), but they showed sensitivities
Table 1
Sensitivity to refractive index changes of different materials generating lossy
mode resonance.
Material RI range Sensitivity Reference
IGZO 1.370–1.385 6700 nm/RIU Ozcariz et al. (2019)
Amorphous silicon 1.33–1.38 5300 nm/RIU Andreev et al. (2005)
ZnO 1.333–1.362 6700 nm/RIU Andreev et al. (2008)
ITO 1.365–1.380 7800 nm/RIU Zubiate et al. (2015)
SnO2-x 1.321–1.326 14500 nm/RIU Arregui et al. (2016)
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Fig. 1. Experimental setup, biosensing device and principle. (A) Detailed microfluidic system and flow channel with the temperature-stabilization system. (B)
The entire experimental setup to monitor in real time the antibody immobilization and the interaction with the D-dimer. (C) Sketch of the proposed D-shaped fiber
biosensor based on a lossy mode resonance approach. (D) A general diagram of the sensing principle and of the LMR wavelength shift corresponding to the D-dimer
capture and the subsequent washing.
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that are at least similar or lower than ITO (Table 1). Moreover, even
though a material with a higher sensitivity is used, its performance in a
microfluidic system should be tested. Therefore, the stability of ITO and
SnO2-x was compared in fluidic conditions. Unlike SnO2-x, ITO experi-
enced some drifts, which reinforced the idea of using SnO2-x instead of
ITO (Del Villar et al., 2019).
In order to obtain the D-shaped fiber configuration, standard single
mode fibers (Corning SMF-28) with a cladding/core diameter of 125/
8.2 μm are used. 17mm of the fiber are progressively polished down
until an attenuation of 1 dB at 1550 nm is attained in high RI matching
oil (1.5 RIU).
Concerning the procedure of coating deposition of the SnO2-x thin
film, the D-shaped fiber is placed inside a DC sputter machine (K675XD
from Quorum Technologies) at a partial pressure of argon of
9× 10−2mbar and an intensity of 90mA, and a coating of around
(160±10) nm was deposited, according to (Chiavaioli et al., 2018).
After the deposition process, the fiber sensor is located inside a
thermo-stabilized microfluidic system (Chiavaioli et al., 2014). The
flow cell allows for control and manipulation of small volumes of liquid
samples as well as temperature stabilization. As shown in Fig. 1A, the
microfluidic system consists of two equal-size pieces (23mm wide,
10mm deep and 100mm long), which can be assembled and sealed
with Parafilm R® sheet interposed between the two parts in order to
assure the water-proofing. The upper one is made of polyetherimide
(ULTEM resin) and the bottom one is made of stainless steel. A mi-
crofluidic channel is fabricated on both bars with the size of
1mm×1mm×50mm, thus attaining a volume of 50 μL, which per-
fectly fits the handling of small liquid samples. An inlet and an outlet
are punched at both sides of the ULTEM piece. In addition, a v-groove
of 0.5mm deep is engraved on both ends of the stainless steel bar in
order to house the fiber sensor, which is finally glued with its jacket to
the v-groove edges using an UV optical flexible adhesive (Norland),
allowing for the mechanical stabilization of the device. The stainless
steel bar of the flow cell is heated with two Peltier cells
(23mm×25mm), whereas a thermistor is inserted into a lateral hole
in the stainless steel bar, as shown in Fig. 1A. A temperature control
system acquires the temperature from the thermistor and drives current
to the Peltier cell in order to adjust the temperature at 30 °C (±0.05 °C).
Finally, the microfluidic system is connected to a peristaltic pump by
means of a premium medical grade thermoplastic elastomer PHI tube,
making it possible to pump the appropriate solution into the flow cell.
The flow rate of each solution varies according to the biological pro-
cedure as detailed in the next section, devoted to the explanation of the
surface functionalization and assay protocol.
The optical spectrum is monitored and recorded from the first phase
of thin-film deposition up to the further biological stages (im-
mobilization and detection) using the experimental setup depicted in
Fig. 1B. A multi-LED light source (HP-83437A) is used as the optical
source that launches light into the optical fiber. In order to control the
polarization state of light, a fiber optics in-line polarizer and a polar-
ization controller are located between the optical source and the D-
shaped fiber sensitive region. Once light passes through the fiber, an
optical spectrum analyzer (OSA, HP-86142A) collects the optical
spectrum and allows the measurement of the LMR resonance wave-
length.
2.3. Surface functionalization and assay protocol
The sketch of the biosensor is displayed in Fig. 1C. As a first step, the
D-shaped fiber surface is coated with SnO2-x. After that, the antibody is
grafted on the sensor surface, according to the following steps:
i) the sensitive region of the fiber is immersed in 2mM (0.04% w/v)
Eudragit L100 copolymer in ethanol for 1min and then is left
drying in air for about 15min until the solvent has completely
evaporated. Eudragit L100 provides the free functionalities, i.e.
carboxylic functional groups, necessary for the antibody im-
mobilization on the sensor surface;
ii) the carboxylic groups are activated by means of an EDC/NHS so-
lution (2 mM/5mM, respectively), which is injected and flowed
over the Eudragit at 14 μL/min when the sensor is safely placed
inside the microfluidic system;
iii) immediate covalent immobilization of the antibodies on the acti-
vated surface is carried out, by injecting a solution of 500 μg/mL
anti-D-dimer in PBS for 1 h at a flow rate of 7 μL/min;
iv) washing with PBS buffer is performed for 5min at a flow rate of
20 μL/min, so as to remove the unreacted antibodies;
v) surface passivation with 1% (w/v) BSA in PBS is implemented: BSA
is injected for 15min at 14 μL/min to block unreacted remaining
active carboxylic groups and to prevent non-specific adsorption on
to the sensing surface.
Once the anti-D-dimer receptor is grafted on the fiber, the assay is
completed by injecting different solutions of D-dimer protein at in-
creasing concentrations that range from 0.1 μg/mL up to 100 μg/mL for
15min each at a flow rate of 7 μL/min. A washing step with PBS is
carried out for 5min at 20 μL/min between each D-dimer protein so-
lution injection in order to measure the surface effect due to the re-
ceptor-analyte binding interaction and, hence, to discard any volume
effect related to the solution refractive index (Chiavaioli et al., 2017b).
Fig. 1D accounts for a general diagram of the sensing principle and of
the LMR wavelength shift corresponding to the D-dimer capture and the
subsequent washing.
Specificity is confirmed in the first experiments by injecting a C-
reactive protein, which is another biomarker for heart diseases like
stroke, while in the other experiments the same model assay is also
performed in human serum diluted 1:10 (v/v) in PBS and undiluted
serum, by spiking D-dimer protein at different concentrations.
The biological steps are carried out within the microfluidic system,
keeping the external temperature as stable as possible at (25± 1) °C
and the flow cell temperature at (30±0.05) °C. This temperature has
been chosen in order to avoid the oscillations of the temperature con-
trol system described in the previous section. In fact, it turns out that a
slightly different temperature with respect to that of the environment
has to be selected to make the temperature as stable as possible for
long-term measurements. All the binding interactions are performed in
situ, and are continuously monitored in real time through the experi-
mental setup of Fig. 1B.
2.4. Gel electrophoresis and immunoblotting
As purity analysis concerns, protein denaturation from the sensing
surface of the fiber is firstly performed by applying a lysis buffer con-
taining urea (7M), thiourea (2M) and DTT (0.5%) for 5min at 95 °C.
Afterwards, protein content is let it precipitate by acetone 0/N at
−20 °C. Later, both D-dimer protein and DD2 anti-D-dimer antibody
(1–5 μg) are re-suspended in 4x Laemmli buffer in the presence of beta-
mercaptoethanol. After that, the biomolecules are separated by sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (12.5% acryla-
mide).
For specificity analysis, DD2 anti-D-dimer antibody were used to
detect potential D-dimer products by Western-blotting using the pro-
cedure described in (Lachén-Montes et al., 2017). Briefly, D-dimer
protein is re-solved in 12.5% acrylamide gels and electrophoretically
transferred onto nitrocellulose membranes using a Trans-blot Turbo
transfer system in 7min (up to 25 V). Membranes are then probed with
the antibody at 1:1000 dilution in 5% non-fat milk. After incubation
with the appropriate horseradish peroxidase-conjugated secondary an-
tibody (1:5000 dilution), the immunoreactivity is visualized by en-
hanced chemiluminiscence (PerkinElmer) using a Chemidoc MP Ima-
ging System (Bio-Rad). Finally, densitometric analysis is performed
with the Image Lab tool (Software Version 5.2).
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The entire previously described technical workflow, which is used
to verify the binding of D-dimer onto the functionalized biosensor
surface, is sketched step-by-step in Fig. 2.
2.5. Protein identification by mass spectrometry
D-dimer (3 μg) is diluted in 4x Laemmli buffer and loaded into a
0.75mm thick polyacrylamide (12.5%) resolving gel. Bands are stained
with Coomassie Brilliant Blue staining and excised from the gel. Protein
enzymatic cleavage is carried out with trypsin (1:20, w/w) for 16 h at
37 °C using the procedure described in (Shevchenko et al., 2007).
Peptides mixtures are separated by reverse phase chromatography
using a NanoLC-Ultra 2D pump system (Eksigent) fitted with a 75 μm ID
column (0.075× 250, Eksigent). During the process, pre-column is in
line with column and flow is maintained all along the gradient at
300 nL/min. Eluting peptides from the column are analyzed using a
Sciex 5600 Triple-TOF system. Tandem MS/MS data acquisition and
protein identification are performed using the procedure described in
(Lachén-Montes et al., 2017; Socorro et al., 2017).
3. Results
The LMR generated with the deposition of a nanometric film of
conductive black tin oxide, SnO2-x, on D-shaped fibers is used to detect
D-dimer/anti-D-dimer interactions. The operation principle consists of
monitoring in real time the interaction between a protein (D-dimer) and
the specific antibody (anti-D-dimer) - the so-called capture antibody -
grafted on the D-shaped fiber, which induces changes in the thickness of
the coating and in the effective RI of the sensing layer. An accurate
determination of this change can be attained by detecting the wave-
length shift of the LMR (λLMR).
3.1. Detection of Human D-dimer in buffer
In order to demonstrate the ability of the nanometric film coated D-
shaped fiber-based biosensor for a label-free detection of D-dimer in
PBS buffer (pH 7.4), its response to different concentrations of D-dimer
protein was analyzed. The capture immobilization, the first part of any
assay protocol, plays an important role in terms of development of the
proposed biosensor. In addition, as it is indicated in Methods section,
monoclonal anti-D-dimer antibodies were selected as biological re-
cognition element (BRE) due to their high affinity and specificity with
D-dimer protein. The results related to this first part of the model assay,
step-by-step described in Methods section, are detailed in
Supplementary Fig. 1. The transmission spectrum of the sensor was
monitored during the entire experiment and the wavelength shift of the
LMR was tracked in real time in order to achieve the sensorgram.
Fig. 3A shows the sensorgram of D-shaped fiber biosensor during the
injection of D-dimer protein at increasing concentrations. The sensor-
gram displays the signal change, compared to the baseline, to D-dimer
solutions ranging from 0.1 μg/mL up to 100 μg/mL. Here, it can be seen
that the LMR wavelength changes with the concentration of D-dimer or,
in other words, the LMR wavelength shifts toward longer wavelengths
as the concentration of D-dimer increases. As in all label-free bio-
sensors, after the injection of the target analyte at different con-
centrations, and the subsequent attainment of a stationary equilibrium,
a washing step with PBS is performed in order to remove all the un-
bound D-dimer. Therefore, the wavelength shift after the washing step
with respect to the signal value before the D-dimer solution injection is
only related to the amount of D-dimer captured by the specific receptor
grafted on the fiber surface and can be directly associated to the D-
dimer concentration.
Fig. 3B accounts for the calibration curve of the biosensor, which
represents the shift of the LMR wavelength as a function of the con-
centration of D-dimer protein. As an additional parameter for perfor-
mance assessment among the biosensors tested, the relative shift of
λLMR (normalized by the initial value of λLMR) is detailed in
Supplementary Fig. 2. The value of each experimental point was ob-
tained by averaging over 15–20 distinct measurements at flow stopped
after each washing step in buffer. As shown in Fig. 3B, the response of
the device exhibits the typical sigmoidal behavior without reaching the
highest values (upper asymptote) where the saturation of the biosen-
sing layer is obtained, because small concentrations of D-dimer have
been explored. The experimental points are fitted by the Hill function
with a R2 regression coefficient of 0.9968. The Hill equation, which is
formally equivalent to the Langmuir isotherm, is a well-accepted
mathematical model that provides a way in which to quantify the de-
gree of interaction between ligand binding sites (Gesztelyi et al., 2012).
A total wavelength shift of 16.78 nm for D-dimer concentrations
varying from the baseline to 100 μg/mL is achieved. From the cali-
bration curve of Fig. 3B, it is possible to extrapolate the limit of de-
tection (LOD) of the biosensor, defined as the signal of the blank plus
three times the standard deviation of the blank (Shrivastava and Gupta,
2011). For the sake of simplicity, the LMR wavelength has been scaled
down at 0 nm in each calibration curve, therefore LODs have been
calculated as three times the standard deviation of the blank (Chiavaioli
et al., 2017b). By looking the detail of the inset of Fig. 3B, the LOD for
the proposed biosensor is 10 ng/mL (50 pM), considering σblank= 16.8
pM (picometer). Moreover, it should be pointed out that the error bars
correspond to the measurements of four identical and independent
sensors (n=4) in order to assess the repeatability and reproducibility
of the proposed biosensor. The LMR device details a response to D-
dimer in PBS in the concentration range of 0.1–100 μg/mL. The
minimum shift of resonant wavelength is 0.232 nm at 0.1 μg/mL,
whereas the maximum shift is 16.78 nm at 100 μg/mL. In addition, in
order to provide a more realistic and reliable assessment of the bio-
sensor performance, the limit of quantification (LOQ) is also evaluated
by defining it as the signal of the blank plus ten times the standard
Fig. 2. Technical workflow used to verify the binding of D-dimer onto the
functionalized biosensor surface. Detachment of D-dimer protein from the
functionalized fiber surface possessing the BRE, its separation through Sodium
Dodecyl Sulphate-PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and, finally,
its detection by Western-blotting (W-b).
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deviation of the blank (Shrivastava and Gupta, 2011). The LOQ for the
proposed biosensor is 80 ng/mL (400 pM).
In order to study the specificity of the biosensors, they are exposed
to different solutions of D-dimer spiked with a non-specific protein, C-
reactive protein (CRP). The results, which are detailed in
Supplementary Fig. 3, clearly show a flat response during the injection
of CRP at 30 μg/mL, which demonstrates a biosensor specificity greater
than 90%. Moreover, the shift of LMR wavelength related to the in-
jection of a solution of 10 μg/mL D-dimer and 10 μg/mL CRP and the
subsequent washing in PBS is roughly 4 nm, perfectly comparable with
that shown in Fig. 3. The same can be said about the 8 nm shift attained
with 30 μg/mL D-dimer and 50 μg/mL CRP. This testifies again the
biosensor specificity and corroborates that the shift of λLMR is directly
associated with the interaction of the D-dimer protein.
Fig. 3. Detection of Human D-dimer protein in PBS. (A) Sensorgram of D-shaped fiber biosensor during injection of increasing concentrations of D-dimer. All the
analyte concentrations from baseline up to 100 μg/mL are displayed, with a total shift of the λLMR of 16.78 nm. (B) Calibration curve of four identical and in-
dependent biosensors (n=4) detecting D-dimer in PBS with the Hill fitting curve of the experimental points. The inset details the wavelength shift and error bar of
the blank and first D-dimer concentrations.
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3.2. Detection of Human D-dimer in human serum
The next step is the implementation of the assay using human serum
samples, in order to investigate the application of the biosensor much
closer to the real situation toward clinical applications. In the same
way, the binding between the antibody and the protein is monitored in
real time during the implementation of the same assay with the D-dimer
spiked in human serum. Two different assays are performed, one with
the serum diluted in PBS (1:10) and the other with undiluted serum.
Fig. 4A details the sensorgram of a D-shaped fiber biosensor in the first
case, while Fig. 4B in the second case. It should be pointed out that the
background wavelength shift experienced in both diluted and undiluted
serums is due to refractive index of the solution in which the D-dimer is
spiked. All the refractive index-based optical sensors are sensitive not
only to the adhesion of molecules on the sensor surface (surface re-
fractive index change), but also to the refractive index of the sur-
rounding medium (volume refractive index change). Both contribute to
the background wavelength shift, even if the second effect can be
considered almost instant when the solution enters the microfluidic
system (Chiavaioli et al., 2017b). It turns out that the background
Fig. 4. Detection of Human D-dimer protein in human serum. (A) Sensorgram of D-shaped fiber biosensor during injection of increasing concentrations of D-
dimer (range 1–100 μg/mL) spiked with serum diluted in PBS (1:10). Inset: specificity test representing the signal change, i.e. the LMR wavelength shift, in PBS after
the injection of serum without the specific analyte under investigation (D-dimer). (B) Sensorgram of D-shaped fiber biosensor during injection of increasing con-
centrations of D-dimer (range 0.5–100 μg/mL) spiked with undiluted serum (top chart). Bottom chart: zoom of the previous sensorgram showing the change of the
signal of interest taken in PBS at flow stopped.
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wavelength shift in the sensorgram achieved with undiluted serum
(Fig. 4B) is larger than in diluted serum (Fig. 4A) because the refractive
index of undiluted serum is higher than that of diluted serum. As de-
scribed in section 2.3, since all the experimental points in the calibra-
tion curves are taken at flow stopped after the washing in PBS buffer,
there is no contribution of the (diluted and undiluted) serum refractive
index in the results, thus all the LMR wavelength shifts will be only due
to adhesion of D-dimer onto the biosensing layer.
In addition, the inset of Fig. 4A shows the specificity test re-
presenting the shift of λLMR in PBS after injection of serum only, without
the specific analyte under test (D-dimer). This shift, taken in PBS before
(baseline) and after the injection of serum, was (0.05± 0.02) nm,
whereas a larger shift is observed in the successive steps when D-dimer
is spiked with serum, indicating that the protein interacted with the
capture antibody with a specificity >90%. The same can be asserted in
the case of undiluted serum (Fig. 4B) with a shift of LMR wavelength of
(0.08±0.025) nm and a specificity >80%.
Fig. 4 reports on the total wavelength shift of 10.49 nm and of
5.67 nm obtained with the two assays in the case of diluted and un-
diluted serums, respectively. In the second case, the total shift is almost
half of the first case and this can be explained considering a greater
difficulty and, hence, a less probability for the analyte to reach the
receptor due to a denser matrix and/or to a more intense electric charge
effect over the biomolecules (Squires et al., 2008). Moreover, the effect
of volume RI change is evident in Fig. 4B if the signal in serum and in
PBS is compared. In fact, the signal change is so big that a zoom of the
interested part is presented to see the signal change in PBS after the
injection of D-dimer solutions in serum and the successive washing.
However, it is worth pointing out that this does not affect the capability
of the biosensor to detect D-dimer at very low concentrations.
Fig. 5 accounts for the calibration curve of the two biosensors when
the assays have been performed with diluted (green symbols) and un-
diluted (blue symbols) serums. The value of each experimental point is
obtained by averaging over 15–20 distinct measurements at flow
stopped after each washing step in PBS as detailed in Methods section.
In these cases, no repeated experiments have been performed (n=1).
Consequently, in this second case of Fig. 5, the error bars referred just
to the above-mentioned procedure.
The LOD for the proposed biosensor is 100 ng/mL (0.5 nM) in the
case of diluted serum, considering σblank= 34 pM (picometer), while it
is a bit higher, 320 ng/mL (1.6 nM), in the case of undiluted serum for
the same reasons discussed previously. In any case, the usual protocol in
clinical applications concerning human samples is to apply a dilution
(1:5 or 1:10) to avoid any matrix effect (Zhang et al., 2014). However,
the results of Fig. 5 detail clearly the ability of the biosensor to properly
work with undiluted human serum. Moreover, the LOQs for the bio-
sensors implemented in human diluted and undiluted serums are
800 ng/mL (4 nM) and 2.4 μg/mL (12 nM), respectively. Even if the
LOQs are higher than the clinical cutoff value, in the case of diluted
serum we are very close to it (800 ng/mL against 500 ng/mL) which
makes us confident that a slight optimization in the optical platform
will allow us the achievement of this objective also considering that the
LOD is 5-fold below the clinical cutoff value.
3.3. Evidence of human D-dimer binding onto the functionalized biosensor
surface
As a further evidence, in order to verify the binding of D-dimer onto
the functionalized biosensor surface having the BRE, a technical
workflow has been developed. It consists of the detachment of D-dimer
protein, then of its separation through Sodium Dodecyl Sulphate-
PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and, finally, of its
detection by Western-blotting (W-b). All the steps are detailed in
Methods section. Fig. 6A shows the results of D-dimer separation by
SDS-PAGE using the Ponceau staining, whereas Fig. 6B details the re-
sults obtained with W-b. It turns out that Ponceau staining is not sen-
sitive enough to detect the presence of D-dimer protein, but is useful
because it does not appear to have a deleterious effect on the sequen-
cing of blotted biomolecules and, hence, is the selected method for
locating them through W-b. In fact, W-b reveals a specific band of
protein detached from the fiber biosensor placed between 25 and
35 kDa (Fig. 6B).
In order to characterize the protein band previously obtained, mass
spectrometry is used to identify the presence of D-dimer. The procedure
Fig. 5. Calibration curves obtained in
human serum. The calibration curves of
two distinct D-shaped fiber biosensors
(n=1) detecting D-dimer in human serum
are displayed, together with the Hill sig-
moidal fitting curves of the experimental
points (diluted serum, blue symbols; un-
diluted serum, green symbols). The inset
details the wavelength shift and error bar of
the blank and first D-dimer concentrations
for both cases.
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is described in Methods section, while the results are presented in
Supplementary Material (Supplementary Table 1 and Supplementary
Figs. 4 and 5). By using the previous mentioned workflow, D-dimer
fragments corresponding to beta- and gamma-chains of fibrinogen are
identified by mass spectrometry, confirming that the D-dimer is cova-
lently bound to the fiber surface.
4. Discussion and conclusions
Due to the pivotal role of D-dimer levels in the cardiovascular area
(Weitz et al., 2017), it is obvious that specific and accurate measure-
ment methods are needed. Nowadays, a divergence exists even using
similar formats (Riley et al., 2016), making the standardization quite
difficult. This discrepancy may be explained by several factors, in-
cluding employment of monoclonal antibodies with varying specifi-
cities and differences in instrumentation used to detect D-dimer.
Here, we report on a LMR-based optical biosensor realized by means
of a SnO2-x nanocoated D-shaped fiber for the detection of specific D-
dimer/anti-D-dimer interactions, providing a sensitive, simple and
label-free biosensing platform for the D-dimer detection. The operating
principle consists of binding of a protein (D-dimer) to an antibody (anti-
D-dimer) grafted on the D-shaped fiber, which induces changes both in
the thickness of the sensitive layer and in the effective RI of the layer
itself. Hence, an accurate determination of this change can be attained
by detecting the shift of the LMR wavelength, which allows monitoring
the binding kinetics by a real-time recording of the optical spectrum.
This feature is combined with the unique and peculiar properties of
optical fibers: small size, immunity to electromagnetic and radio-
frequency interferences, capability to be used in harsh environments,
for remote sensing and within multiplexed sensing schemes, and, most
importantly, light management.
In this case, D-dimer binding is specific in the presence of not spe-
cific proteins (i.e. CRP), and in the presence of human serum, a highly
complex biological matrix constituted by more than 10,000 different
kinds of proteins (Nanjappa et al., 2014). The response time of the
biosensor, roughly 10–20min, can be considered comparable with
other fiber-based biosensing platforms (Chiavaioli et al., 2017a), taking
into account that the measurements have been carried out in complex
matrices. Interestingly, an outstanding LOD of a 10 ng/mL (in buffer
matrix) and 100 ng/mL (in human serum) has been obtained. In addi-
tion, it is important to note that the sensitivity of the device may be
increased by selecting an overlay material with a higher RI than SnO2-x,
which should allow improving the LOD (Del Villar et al., 2012).
Nevertheless, the LOD obtained in human serum is below the clinical
cutoff value of 500 ng/mL indicated both for plasma and for serum
(Linkins and Takach Lapner, 2017; Marill, 2008; Weitz et al., 2017) (a
higher level is indicated in (Tan et al., 2017)), which is a key advance
towards theranostic treatments of VTE for personalized medicine.
While configurations reported up to now are rather complex with
time-consuming methods, such as ELISA tests or fluorescence-based
techniques, our label-free approach greatly simplifies the measurement
and the device itself compared to other biosensors realized for D-dimer
detection (Bernard et al., 2010; Bourigua et al., 2010; Di Nisio et al.,
2007; Rowe et al., 1998; Shimony et al., 2011). Clearly, commercially
available ELISA kits or other labelled-based techniques can attain
comparable or sometimes better results with all the typical drawbacks
of such approaches, like sample manipulation and so on. Moreover, the
main novelty of the device presented here is the ability to monitor in
real time every step of the process, by recording the evolution of the
central wavelength of the optical resonance generated with the thin-
film deposited on a special D-shaped fiber.
On the other hand, proteomics is considered one of the ideal plat-
forms for biomarker characterization and translation (Geyer et al.,
2017). In particular, mass spectrometry is widely used to precisely
identify proteins from complex mixtures (Aebersold and Mann, 2016),
matching a list of experimental peptide masses with the calculated list
of all peptide masses of each protein in a database (Aebersold and
Mann, 2003). However, the application of mass spectrometry based
proteomics in biosensing design is scarce. For this purpose, a pipeline
has been stablished consisting of: i) protein detachment from the fiber
surface, ii) immunodetection, iii) protein digestion and subsequent
peptide cleaning, iv) mass spectrometry-based proteomics, and v)
bioinformatics. This bottom-up workflow has allowed us to unequi-
vocally verify the attachment of D-dimer to the fiber surface and to
demonstrate the ability of the technology platform to specifically
(>90%) recognize D-dimer and its reliability. Despite further devel-
opments are needed to the implementation of the proposed device for
clinical applications, this straightforward approach potentially re-
presents a paradigm shift in the development of a fast, simple, high-
specificity and label-free biosensing platform, which can be applied to
speed up diagnostic healthcare processes of VTE toward an early di-
agnostic and personalized treatment system.
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